Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

• Elissa Malkin,

  Affiliation Clinical Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Ram Yogev,

  Affiliation Pediatric, Adolescent and Maternal HIV Infection, Ann & Robert Lurie Children's Memorial Hospital, Chicago, Illinois, United States of America

  ⨯
• Nazha Abughali,

  Affiliation Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America

  ⨯
• Joseph Sliman,

  Affiliation Clinical Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• C. Kathy Wang,

  Affiliation Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America

  ⨯
• Fengrong Zuo,

  Affiliation Research & Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Chin-Fen Yang,

  Affiliation Research & Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Mark Eickhoff,

  Affiliation Clinical Operations, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Mark T. Esser,

  Affiliation Research & Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Roderick S. Tang,

  Current address: International AIDS Vaccine Initiative, AIDS Vaccine Design & Development Laboratory

  Affiliation Research & Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Filip Dubovsky

  * E-mail: dubovskyf@medimmune.com

  Affiliation Clinical Development, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯